StockData
Definium Therapeutics, Inc. logo

Definium Therapeutics, Inc. (DFTX) stock

DFTXNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/30
$29.38−0.78 (-2.59%)

Close on Nov 17, 2026Market cap $3.95BP/E –Yield –

Definium Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Definium Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$227.54M. For fiscal 2025 it was -$166.31M. The highest annual figure on record is -$33.03M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$166.31M–
FY2024Dec 31, 2024-$103.92M–
FY2023Dec 31, 2023-$93.87M–
FY2022Dec 31, 2022-$66.33M–
FY2021Dec 31, 2021-$93.85M–
FY2020Dec 31, 2020-$33.03M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$75.08M–
Q1 FY2026Mar 31, 2026-$59.22M–
Q4 FY2025Dec 31, 2025-$47.58M–
Q3 FY2025Sep 30, 2025-$45.67M–
Q2 FY2025Jun 30, 2025-$40.90M–
Q1 FY2025Mar 31, 2025-$32.16M–
Q4 FY2024Dec 31, 2024-$32.46M–
Q3 FY2024Sep 30, 2024-$24.79M–
Q2 FY2024Jun 30, 2024-$24.46M–
Q1 FY2024Mar 31, 2024-$22.20M–
Q4 FY2023Dec 31, 2023-$22.21M–
Q3 FY2023Sep 30, 2023-$21.62M–
Q2 FY2023Jun 30, 2023-$29.18M–
Q1 FY2023Mar 31, 2023-$20.86M–
Q4 FY2022Dec 31, 2022-$13.90M–
Q3 FY2022Sep 30, 2022-$16.98M–
Q2 FY2022Jun 30, 2022-$16.94M–
Q1 FY2022Mar 31, 2022-$18.51M–
Q4 FY2021Dec 31, 2021-$17.56M–
Q3 FY2021Sep 30, 2021-$17.23M–
Q2 FY2021Jun 30, 2021-$45.22M–
Q1 FY2021Mar 31, 2021-$13.85M–

More Definium Therapeutics figures

See a number that looks wrong?